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A STUDY ON CORRELATION OF EJECTION FRACTION AND 
HBA1C AMONG NON DIABETIC UNSTABLE ANGINA 
PATIENTS 
INTRODUCTION  
Dr. Huisman and Meyering were the first to isolate Hemoglobin A1c  from other 
different types of Hemoglobin(1) . They used  chromatographic column method for 
isolation of HbA1c in 1958.  HbA1c was initially portrayed as a glycoprotein by 
Bookchin and Gallop in 1968 however its increase  in patients with diabetes 
Mellitus was depicted by Samuel et al in 1969. The use for HbA1c as monitoring 
tool in the control of blood sugar levels in diabetic patients was proposed in 1976 
by Anthony Ceremy . 
The nomenclature came from the fact , on the basis of cation exchange 
chromatography the first separated hemoglobin is HbA . On the order of elution 
they are further subclassified into HbA1a HbA1b , HbA1c. 
The pathogenesis of HbA1c causing damage to the body metabolism is by two 
distinct process (2 ). 
 First is by increasing the highly reactive free radicals which are present in the 
blood cells .These free radicals also alter the blood cell membranes . These  
alterations lead  to increased  blood cell aggregation which further leads to 
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increased blood viscosity  resulting in impaired  blood flow through the organs. 
Second  mechanism is by increasing the inflammatory process finally resulting in 
atherosclerotic plaque, these changes finally Impact the permeability of the inner 
surface of the endothelium causing leakage. 
 The production of  Pro- inflammatory proteins like Monocyte Adhesion Protein 
which promotes the aggregation of macrophages in the vessel wall is also elevated 
leading to atheroma formation.  
This glycated hemoglobin pass through the vascular smooth muscle causing 
inactivation of acetylcholine induced endothelial relaxation by its affinity and 
bonding to nitric oxide  preventing  the normal functions of nitric oxide .  
Ultimately the inactivation of nitric oxide leads to vasoconstriction and increased 
plague formation. The degradation of blood cells also release heme from them 
leading to oxidation of endothelial and low density lipoprotein resulting in plague 
formation . 
Though the process of protein synthesis is a common one ,  the case with 
hemoglobin is different, as it is  a non enzymatic reactions with glucose moiety and 
the N terminal portion of the beta chain of haemoglobin. This leads to  formation  
of a schiff’s base which later on gets converted into 1 - deoxy fructose .This above 
process is an example of Amadori rearrangement.   
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REVIEW OF LITERATURE  
In diabetic patients the higher blood glucose levels leads to the attachment of 
glucose molecules to  hemoglobin in the red blood cells(3).  The longer the duration 
of elevated blood glucose level the higher is the bond between  glucose and 
hemoglobin in the red blood cells .Once  the hemoglobin molecule is glycated  it 
cannot be reverted back to the previous free state .  The increase in glycated 
hemoglobin reflects  the level and duration of the Rbc’s exposure to increased 
sugar levels. So the assessment of glycated hemoglobin facilitates the effectiveness 
of therapy and further helps in the monitoring of sugar levels in diabetic patient. 
The lifespan of a red blood cell is about 120 days in men and  106 days in women, 
So the increased level of glycated hemoglobin reflects the increased blood sugar 
levels of the patients over a period of 120 days. 
 
Measurement of HbA1c 
A wide variety of methods are used to detect glycated hemoglobin HbA1c.(3) 
 they include laboratory testing like 
 High Performance Liquid Chromatography 
 Immuno Assay 
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 Enzymatic Method 
 Coupling Electrophoresis 
 Bromide Affinity Chromatography  
The mechanism used in devices are 
 Immunoassay 
 Bromide Affinity Chromatography 
 
 INTERPRETATION 
The following factors alter the results of HbA1c testing 
 Analytical technique 
  Age of the subject 
  Biological variation 
 HbA1c values  vary between individuals with similar average blood glucose levels 
as much as 3% (3) .The reliability of HbA1ctesting is questioned in  conditions like   
 Blood loss - anaemia   
 Polycythemia   
 After blood transfusion 
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 Renal diseases  
 Liver failure  
 Erythropoietin treatment 
 
American Diabetes Association classified (4)patients according to HbA1c as 
 Normal -  HbA1c less than 5. 6 
 Prediabetes /  Impaired Fasting Glucose /  Impaired Glucose Tolerance -  
HbA1c between 5.7 to 6.4 
 Diabetes mellitus -  HbA1c more than or equal to 6.5 
 
Various studies like VKPDS , ACCORD ( action to control cardiovascular risk in 
diabetes mellitus )  estimated the \ risk of diabetic complications to get reduced by 
3% for every 1mmol  decrease in  HbA1c . They include Diabetic Retinopathy 
Diabetic Nephropathy,  Diabetic Neuropathy and Macrovascular complications . 
 The target for HbA1c should be individualized by the  physicians  based on the  
patient health status  and weighed  against the impending risk of hypoglycemic 
episodes. This  takes into consideration the patient's ability avert  or respond to 
their own hypoglycemic episodes. 
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Increased values of HbA1cindicates the long term complications like Coronary 
Artery Disease,  Stroke , Heart failure,  Renal failure , Blindness , Neuropathy , 
Erectile dysfunction  and gangrene etc. Improper blood sugar control may lead to  
impaired wound healing  after surgery in many patients and the risk of infection 
increases in those subset of patients(2) . 
 Lower levels of HbA1c than the expected level  is usually found in patients with 
shortened RBC lifespan like  
 Glucose 6 phosphate dehydrogenase deficiency 
 Sickle cell disease  
 Any disease that affects the red cell life expectancy 
In specific conditions like blood transfusion the HbA1c values maybe spuriously 
low in recipients  because the new RBC would have been exposed to high sugar 
levels only for a short period of time giving  false low values  under estimating the 
average blood sugar levels. 
 Spuriously high  HbA1c levels are seen in patients with  increase  RBC lifespan 
such as vitamin B12 or Folic acid deficiency 
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HbA1c percentage  Average blood glucose 
levels (mg/dl)  
Blood glucose range        
( mg/dl) 
5 % 97  76-120 
6% 120 100-152 
7% 156 120-185 
8% 183 147- 215 
9% 212 170-248 
 
INDICATIONS (6) 
HbA1c testing is recommended during the confirmation  and  to monitor the 
treatment of diabetes . A single result of HbA1c  gives a wide variety of 
information when compared to a  fasting blood glucose level report. The 
advantages of HbA1ctesting over fasting blood glucose levels are 
 Patients do not have to fast while testing for  HB a1c 
 Hba1c gives Information about patient's glycemic status over a period of 3  
months 
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 Better predictor of complications of diabetes mellitus 
  Frequency for  HbA1c testing in Diabetic population (6) 
Diabetes mellitus type 1  3 to 4 times per year 
 Diabetes mellitus type 2  2 to 3 times per year 
 
In pregnancy the diagnosis of diabetes mellitus involves testing for fasting blood 
sugar levels , postprandial blood sugar levels and glucose  tolerance test.  There is 
only very little  role for HbA1c testing in pregnancy because of alterations in 
hematological parameters. 
Studies Around The World had also documented that HbA1c has predictive value 
in assessing the cardiovascular mortality during an acute coronary syndrome 
however they are not equivocal as they stem  from various studies which had 
different patient selection ideas and different therapy for therapy offered to the 
patients. 
 Although many studies in the world have assessed the predictive value of 
HbA1cin acute coronary syndrome patients among diabetic population(7),  only 
very few studies have assessed  the role of HbA1c in predicting the outcome of 
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acute coronary syndrome among nondiabetic population. However the results of 
the study vary greatly.  
UNSTABLE ANGINA (5) 
Definition :- 
 New onset (< 2 months ) angina , that is severe and /or frequent ≥3 
episodes / day  
 Accelerating angina that is those with chronic stable angina who develop 
angina which is distinctly more frequent, severe , prolonged or 
precipitated by less exertion than previously  
  Angina at  rest. 
CLASSIFICATION OF UNSTABLE ANGINA (5) 
CLASS DEFINITION  
Class I New onset of severe angina or accelerated 
angina with no rest pain  
Class II Angina at rest within past month but not within 
preceding 48 hrs ( angina at rest , subacute 
Class III Angina at rest within 48 hrs  
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CLINICAL CIRCUMSTANCES 
A ( secondary angina )  Develops in the presence of an extracardiac 
condition that intensifies MI 
B ( primary angina ) Develops in the absence of an extracardiac 
condition 
C ( post infarction 
angina ) 
Develops within 2 weeks after acute MI 
 
Worldwide varieties of theories have been proposed about the pathogenic 
mechanisms  of  Unstable Angina.  However none of the theories have been able to 
explain the mechanisms  adequately.  
Initially many patients with Unstable Angina were found to have atheromatous 
plagues  in their coronary arteries(8).   So a progressive stenosis caused by a large 
plague was thought to be the reason for ischemic symptoms. However this theory 
failed due to the fact when assessing the coronary arteries of patients who had 
chronic stable angina for 2 years and the patient who had Unstable Angina seemed 
similar . Other patients who had chronic stable angina had larger atheromatous 
plagues than those with Unstable Angina who presented as initial manifestations of 
ischemic heart disease.  
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PLAGUE  FISSSURE THEORY (9) :- 
The second theory which was better than the above was Plague Fissure Theory . 
This theory says  that  the sudden fissuring or rupture of the plague is the main 
pathogenic mechanism for unstable angina. This fissuring or rupture causes the 
highly thrombogenic endothelium get exposed to the circulation resulting in the 
development of platelet rich thrombus. The developed thrombus obstructs the 
blood flow but do not completely occlude the vessel causing ischemia rather than 
infarction.  
Evidence against Plague Fissure  Theory (10 ) - The First evidence is from clinical 
observations . We expect the thrombosis at the site of plague rupture to be an acute 
event . So the patients die or recover from the episode. In both these cases the 
course of illness short. But in Unstable Angina the symptoms wax and wane over 
several days or weeks. The mortality is high initially and develops gradually as the 
time progresses without achieving a steady state. The second evidence is from post 
mortem changes.  The postmortem studies of the patients died due to Unstable 
Angina did not have evidence of formed atheromatous plagues in the coronary 
arteries. In addition there was a significant proportion of patients who died due to 
other causes have evidence of plague fissure with or without thrombosis which 
makes it a nonspecific finding . 
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INFLAMMATION THEORY (11) :- 
The explanation that inflammation could be the trigger factor in development of 
Unstable Angina was able to explain both clinical and postmortem observation in 
patient who died of unstable angina .In short the inflammatory cascade triggered 
the endothelium leading to thrombosis of the vessel.Support of this theory would 
be anti inflammatory agents decrease the progression in Unstable Angina. Patients 
died  of Unstable Angina had  inflammatory infiltrates in the post mortem 
examination of coronary arteries. However even patients who died of non cardiac 
illness also have inflammatory infiltrates in the coronary arteries.  From these 
statements  we infer that the progression of patients with Unstable Angina was 
linked  to the severity of inflammatory process. Serum CRP levels can be used as a 
marker for inflammatory process as they indicate interleukin 6 release which 
indirectly indicates interleukin 1 release (12). It is easy to measuren and  it has a half 
life of 19 hours. Serum CRP levels are not increased in patients with variant angina 
which was caused by spasm however severe they might  be.  But they are increased 
in patients with Unstable Angina in whom necrosis has happened. This indicate 
that CRP levels can be used as a marker in Unstable Angina. 
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EJECTION FRACTION (5) 
It is the fraction of blood ejected from a ventricle of the heart during each systole.  
It is calculated by the formula ejection fraction is equal to Stroke Volume / End 
Diastolic Volume. Normal LVEF is the capacity of the left ventricle to pump the 
blood during systole into systemic circulation. RVEF is the capacity of the right 
ventricle to pump the blood during systole into pulmonary circulation. Ejection 
fraction is best calculated by echocardiography.  
Other methods to calculate ejection fraction are (5) 
 Computerised Tomography 
  Magnetic Resonance Imaging 
  Ventriculography 
  Single Photon Emission Computerized Tomography 
   Radionuclide Angiography 
  Muga Scanning 
 In history the gold standard for measurement of ejection fraction is  
ventriculography. 
 In MUGA scanning a radioisotope is injected into the blood and the flow  is 
detected.  
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Heart  Failure is classified on the basis of  ejection fraction into Heart Failure With 
Preserved Ejection Fraction And Heart Failure With Reduced Ejection Fraction. 
 
Normal Left Ventricular Ejection 
Fraction 
 66 ± 6 
 Normal Right Ventricular Ejection 
Fraction 
67  ± 4.6 
 
The blood volumes in the right ventricle equals that of the left ventricle and  the 
ejection fraction of the right ventricle matches with that of the left ventricle under 
normal physiological conditions . Damages  to the muscles of the heart like 
Myocardial Infarction, Cardiomyopathy ,Atrial Fibrillation decrease ejection 
fraction of the heart . Ejection fraction has a prognostic value in the evaluation 
treatment and management of heart failure.  
DIAGNOSIS  (5) 
ELECTROCARDIOGRAM  (13) 
In patients who have Unstable Angina the ECG features suggesting it include 
inversion of T wave, transient ST segment depression.  The occurrence of deviation 
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in ST segment even if it is only 0.05 millivolt is a very important sign of adverse 
events in patients who have clinical features classical of unstable angina. The 
changes in T waves are less specific but they are sensitive for ischemia. The 
occurrence of deep inversion in T waves greater than 0.3 millivolt and occurrence 
of new T wave changes which were not present earlier are more significant. 
In patients with myocardial infarction there is elevation of ST segment. The 
elevation in the leads occurs in correspondence to the territory of heart involved. The 
arterial localisation of obstruction can be made out to an extend from the 
electrocardiogram. The other changes include formation of q waves and loss of R 
waves. Most patients who have elevation in the ST segment eventually develop q 
waves but its magnitude depends on the reperfusion status. 
SERUM BIOMARKERS ( 14) 
After an injury to cardiac muscle cell there is leakage of several cardiac proteins into 
the circulation. The levels at which these cardiac bio markers can be detected 
depends on molecular weight, local blood, intracellular location of enzymes and 
lymphatic flow. When the levels of cardiac markers rise to a level such that it 
exceeds the lymphatic clearance, these biomarkers become detectable in blood. 
Cardiac specific troponin T and troponin I are not normally detected in blood but 
when an attack of injury to cardiac muscle occurs their levels get increased by twenty 
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folds. Now cardiac troponin I and T are the most preferred biomarkers of injury to 
cardiac muscle. They are particularly useful when we have doubt of skeletal muscle 
injury and in very small MI in which the levels of creatine phosphokinase is 
undetectable. For about seven to ten days after myocardial infarction we can detect 
the levels of cardiac troponin T and troponin I. Creatine phosphokinase levels are 
elevated within four to eight hours and in about forty eight to seventy two hours their 
levels return to normal. The most important disadvantage of using creatine 
phosphokinase as a cardiac biomarker is that the specificity for cardiac injury is 
lacking and it will be elevated in conditions causing injury to skeletal muscle 
including trauma, crush injury, injection, and rhabdomyolysis. This drawback can 
be reduced by using the isoenzyme of creatine phosphokinase which is CK MB.  
ECHOCARDIOGRAPHY 
Regional motion wall abnormalities may be present. Echo can be very useful tool 
for diagnosing coronary artery diseases in which ECG are inconclusive. ECHO can 
be used to assess the function of the left ventricle post infarction. Right ventricular 
infarction, aneurysm, thrombus and pericardial effusion can be assessed .Two major 
complications of myocardial infarction which can be diagnosed using ECHO include 
acute regurgitation of mitral valve and rupture of the ventricular septum. However 
in patients with Unstable Angina, the role of echo in dignosis is limited. It provides 
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certain useful information like ejection fraction, chamber hypertrophy and 
dilatations.  
 
CORONARY ANGIOGRAPHY 
Patients who have Unstable Angina depending upon the TIMI score patient who fall 
under category two and three must be subjected to angiography and if critical 
occlusion of arteries is present they must be subjected to intervention.  
 
INDICATORS OF POOR PROGNOSIS IN UNSTABLE ANGINA 
PATIENTS (15) 
 
 Features  of  congestive cardiac failure during initial period of 
hospitalisation. 
 Premature ventricular beats greater than 10 per hour before discharge 
 Reduced left ventricular ejection fraction (<50%)  
 Post infarction angina 
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MANAGEMENT 
The management of unstable angina is similar in Diabetic and non -diabetic subjects  
PRIMARY PREVENTION 
The steps taken to prevent the development of risk factors for coronary artery 
disease constitute primary prevention.  
LIFESTYLE CHANGES DIET AND EXERCISE 
The people must be encouraged to take a diet rich in fibres, vegetables, plant sterols 
and low in saturated fatty acids. The people must be encouraged to exercise. 
According to the AMERICAN ASSOCIATION OF DIABETES it is recommended 
that one should exercise for at least thirty minutes per day for five days in week to 
prevent occurrence of cardiovascular complications. Physical activity need not be 
exercise as such and might include day to day activities like washing, cleaning, 
gardening etc… 
WEIGHT REDUCTION   
Studies have shown than consuming a diet less in carbohydrate causes reduction in 
weight drastically only in the initial stages but in order to have continuous 
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reduction in weight dietary restriction must be combined with increased physical 
activity . 
AVOID SMOKING  
Smoking causes release of toxic substances which injures the vascular endothelium 
and causes vasoconstriction. Hence both active and passive smoking should be 
avoided. 
CONTROL OF DYSLIPIDEMIA (15) 
All  patients who have a blood LDL level of greater than 70 mg/dl should be started 
on statins. Patients who have high levels of triglycerides should be started on 
fibrates.  
CONTROL OF   HYPERTENSION 
JNC 8 guidelines should be followed for control of hypertension. The target level of 
BP control according to JNC 8 guidelines is 140/90 mm of hg and ace inhibitors are 
the choice of drugs for control of hypertension. 
SPECIFIC THERAPIES 
Thrombolytic therapy is contraindicated in Unstable Angina and NSTEMI. Low 
molecular weight heparin is preferred over unfractionated heparin .In high risk 
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patients PCI is preferred over conservative treatment and this results in reduction of 
mortality and morbidity.  
ANTI THROMBOTIC AGENTS 
It reduces the thrombus and maintains patency of occluded artery.  Diabetic patients 
have increased platelet activation and accelerated turnover of platelets. All the 
patients of diabetic with CAD need higher doses of aspirin with additional 
antiplatelet drugs like clopidogrel or ticlopidine. 
BETA BLOCKERS 
It block the adrenergic stimulation and prevent ventricular remodelling and improve 
left ventricular function .It reduces the infarct size and decreases the incidence of 
arrhythmia and improve the survival. Beta blockers also reduce the recurrent 
ischemia and reinfarction. 
ACE INHIBITORS AND ARB 
It prevents the ventricular remodelling and subsequent reduction of cardiac failure 
.it also reduces the recurrent infarction .It delays renal dysfunction . 
STATINS 
It confers long term protection from cardiovascular events in patients recovering 
from Unstable angina and also reduces the complications. 
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IMPAIRED GLUCOSE TOLERANCE  
Impaired glucose tolerance is also called as Pre-diabetes(6) . It is nothing but increase 
blood sugar levels waving between 110 to 126 mg/dl in fasting and between 140 to 
199 after two hours postprandial.It should be confirmed with 75 gram glucose 
tolerance test at least twice. About 80% of impaired glucose tolerance patient  will 
end up in diabetes mellitus.. 
Impaired glucose tolerance is a transition state from normal glycemia to frank 
diabetes.Type 2 Diabetes mellitus and impaired glucose tolerance are a part of 
metabolic syndrome , Which is also called as syndrome X .  This syndrome X include 
Insulin Resistance,  Hypertension ,  Obesity ,  Hyperinsulinemia  And Dyslipidemia 
(16) .  Impaired glucose tolerance is a major risk factor for diabetes with 20 to 50% 
of affected patients progressing to diabetes within 10 years.  Progression 2 diabetes 
is not associated with microvascular complications, Nephropathy Retinopathy , 
Neuropathy.   
 ETIOLOGY OF GLUCOSE  INTOLERANCE (17) 
 Obesity is the powerful determinant of glucose intolerance 
 genetic defects of Beta cell function 
 Mutation on chromosome 12,  Hepatocyte nuclear factor 1, Alpha - MODY3 
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 Mutation on chromosome 7 p ,  Glucokinase gene - MODY 1  
 Mutation on chromosome 20, HNF 4  
 Point mutation in mitochondrial DNA 
 Defects in insulin action 
 Structure and function of insulin receptors,  post receptor signal transduction 
pathways. 
  Type a insulin resistance 
  Leprechaunism 
  Rabson- Mendelhall syndrome 
  Lipoatrophy 
 Disease of exocrine pancreas 
 Pancreatitis 
 Trauma 
  Infection 
  Pancreatectomy 
  Pancreatic cancer 
  Cystic fibrosis 
  Hemochromatosis 
  Fibrocalculous pancreatopathy 
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 Endocrine diseases(18) associated with excess production of insulin antagonist 
 Acromegaly 
  Cushing syndrome 
  Glucagonoma 
  Pheochromocytoma 
  Hyperthyroidism 
  Somatostatinoma 
  Aldosteronoma 
 
 Drugs or chemical agents (19 ) with adverse effects on glucose tolerance 
  Thiazides 
 Glucocorticoids 
  calcineurin inhibitors such as  cyclosporine  and tacrolimus 
 Oral contraceptives 
 Beta adrenergic agonists 
 Nicotinic acid 
 Thyroxine 
 Pentamidine 
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 Alpha interferon 
 Atypical antipsychotics especially clozapine  and olanzapine  
 Antiretroviral drugs 
 infection associated with beta cell destruction 
 Rubella 
 Coxsackie virus b 
  Mumps 
  Cytomegalovirus 
  Adenovirus 
 
 Genetic syndromes that predisposes an individual to impaired glucose tolerance 
 Down syndrome 
  Klinefelter syndrome 
  Turner syndrome 
  Wolfman’ syndrome 
  Frederick Ataxia 
 Immune mediated cause of impaired glucose tolerance 
 Stiff person syndrome 
 Anti insulin receptor abnormalities 
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 Glucose intolerance  may be present in many patients with cirrhosis due to 
decreased hepatic glucose uptake and glycogen synthesis. Other mechanisms include 
hepatic and peripheral resistance  to insulin and serum hormonal abnormality. 
Glucose intolerance maybe also seen in uremia due to peripheral resistance to the 
action of insulin.   
Actually  glucose tolerance will not produce any symptoms or  signs  but silently it 
will affect internal organs like heart, kidney,  nerves  and blood vessels(18) .Impaired 
glucose tolerance patient are more prone to develop myocardial infarction, systemic 
hypertension , both macrovascular and microvascular complications(20) 
Microvascular complications include ( 21) 
  Retinopathy 
  Nephropathy 
  Neuropathy 
 Macrovascular complications include 
  Coronary Arterial disease 
  Stroke 
 Renal papillary necrosis 
  lower limb ischemia 
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SYMPTOMS AND SIGNS (22 ) 
 Normally impaired glucose tolerance patients will not exert any symptoms  but  
fatigue , giddiness,   sweating  are not specific complaints that are common in 
Prediabetes. 20 to 30% of Pre diabetic patients have acanthosis nigricans which is a 
blackish discoloration of neck folds skin , axilla and groin. 
PATHOGENESIS OF IMPAIRED GLUCOSE TOLERANCE 
 Direct tissue ischemia (23)caused by failure of reactive vasodilation is more 
important in small vessel complications with inflammatory changes and defects of 
thrombolysis  allow  clot formation and potentiate large vessel complications such 
as myocardial infarction and stroke. Insulin resistance, free fatty acid and 
inflammatory cytokines released from adipocytes appear more important than 
hyperglycemia in causing chronic endothelial injury and thrombus formation(24).  
This may explain why insulin resistance is associated with complication especially 
Myocardial Infarction in patients who are still normoglycemic.  Direct tissue injury 
caused by hyperglycemia maybe more important to microvascular complications 
especially neuropathy. 
 Insulin resistance and compensatory hyperinsulinemia  (25)are linked to metabolic 
syndrome which is the combination of abdominal obesity, hypertension and 
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dyslipidemia that is associated with increased vascular disease. Complications are 
more frequent in insulin resistance patient even before the development of 
hyperglycemia.  
Insulin resistance disrupts insulin regulation of endothelial nitric oxide synthase 
activity. Insulin resistance was correlated with increased plasma expression of 
asymmetric Dimethyl Arginine (26)  an endogenous nitric oxide synthase inhibitor.  
Insulin binds with insulin receptor and phosphorylates endothelial nitric oxide 
synthase. This phosphorylation is lost in insulin resistance. Endothelial proliferation 
is also a consequence of mitogen signalling associated with insulin resistance. As 
hyperinsulinemia develops mitogen-activated protein kinase signalling increases , 
promoting vascular proliferation.  
 Obesity (27) and insulin resistance promote production of free fatty acids from 
adipocytes. Excessive free fatty acid induced changes in vasoregulation promote 
chronic endothelial injury.  Free fatty acid  inhibit endothelial nitric oxide synthase  
activation and it helps in generation of reactive oxygen species by increasing 
peroxidation.  Hormones secreted from adipocytes termed Adipo-cytokines (28) plays 
an important role.  Altered secretion of to Adipo-cytokines, Tumor Necrosis Factor 
Alpha and Adiponectin in obesity and impaired glucose tolerance contributes to 
endothelial injury and promote early vascular complications.  TNF Alpha is a 
Proinflammatory adipokine that act through sphingolipid second messenger 
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Ceramide. Ceramide(29) induces oxidative stress and apoptosis in endothelial cells 
which causes accelerated atherosclerosis .TNF Alpha activation of Ceramide also 
accelerates insulin resistance by inhibiting insulin receptor coupling to IRS 1.  
Adiponectin is an adipocyte -derived peptide that inhibits vascular smooth muscle 
cell proliferation and appears to inhibit  macrophage mediated endothelial injury. 
Adiponectin secretion is reduced in obesity and hyperglycemic states. Increase in 
type 2 diabetes mellitus is related to life  style changes(30) that resulted in overweight, 
obesity and decreased physical activity levels . These environmental changes 
superimposed on genetic predisposition increase insulin resistance which  in concert 
with progressive beta cell failure resulting in rising glycemia in non diabetic 
range(31).  During Pre-diabetic state the risk of cardiovascular disease event is 
moderately increased with development of diabetes(32)  however there is a loss 
increase in risk of cardiovascular diseases as well as for long term complications 
affecting eyes Kidneys and Nervous system. The complications of diabetes which 
are the cause of major morbidity and mortality or related to its duration chronic level 
of glycemia (33)and other risk factors. 
 Although both isolated impaired fasting glucose and isolated impaired glucose 
tolerance are  insulin resistance states they differ in their site of insulin resistance(34).  
People with isolated impaired fasting glucose predominantly have a partial insulin 
resistance and normal muscle insulin sensitivity . People  with isolated impaired 
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glucose tolerance have normal to slightly reduced  hepatic insulin sensitivity(35) and 
moderate to severe insulin resistance.  
Individuals with both impaired fasting glucose and impaired glucose tolerance 
manifest both muscle and hepatic insulin resistance(36). Pattern of insulin secretion 
also differ between impaired fasting glucose and impaired glucose tolerance.  People 
with isolated impaired fasting glucose have decrease in first phase of insulin 
secretion ( 0 to 10 min ) after a glucose load. However late phase of insulin secretion  
( 60 to 120 minutes) appear normal in patients with isolated fasting glucose. Isolated 
impaired glucose tolerance also has defect in early phase insulin secretion in 
response to oral glucose load (37 ) and in addition has severe deficit in late phase 
insurance  secretion also.  Combination of hepatic insulin resistance and defective 
insulin secretion in isolated impaired fasting glucose results in excessive fasting 
hepatic glucose production accounting for fasting hyperglycemia. The impairment 
in early phase insulin response  in  combination with hepatic insulin resistance result 
in excessive early rise of plasma glucose in first hour of oral glucose tolerance test.  
However preservation of late insulin secretion combined with normal muscle insulin 
sensitivity allows glucose levels to return to preload values in isolated impaired 
fasting glucose. In contrast in  isolated impaired glucose tolerance the defective late 
insulin secretion combined with muscle and hepatic insulin  resistance results in  
prolonged hyperglycemia after a glucose load. Nowadays fasting plasma glucose 
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and 2 hour oral glucose tolerance test is preferred to diagnose hyperglycemic States.  
The prevention of delay in diagnosing glucose intolerance  should lead to decrease 
in duration dependent diabetes related macrovascular and microvascular 
complications (38). One of the major reason to recommend therapeutic interventions 
for individuals with impaired fasting glucose or impaired glucose tolerance is the 
potential to reduce long to increase risk of cardiovascular diseases associated with 
diabetes . The strong Association between diabetes and obesity indicate that our first 
priority is maintenance of healthy weight and obesity prevention (40).  All individuals 
who are overweight or obese regardless of their blood glucose values should be 
intensively counseled to lose weight and to exercise regularly. Although several drug 
successfully reduce the progression 2 diabetes , Metformin was the first drug shown 
to be very effective.  Acarbose appears to be effective as Metformin.  But many 
patients cannot tolerate the gastrointestinal side effects of Acarbose. . Orlistat is 
similar to Acarbose  in effectiveness and is poorly tolerated. It is an over the counter 
drug.  Recently DREAM study indicated that Rosiglitazone was effective in delaying 
and preventing  diabetes but it is costly and it is associated with sevenfold increase 
of heart failure. 
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ORGAN SPECIFIC COMPLICATIONS 
  EYE  Retinopathy -  Microvascular  aneurysms and rupture leads to non 
hemorrhagic retinopathy. This is important clue  indicating that  the patient is 
progressing into type 2 Diabetes mellitus. 
 CARDIOVASCULAR SYSTEM(41) 
 First system affected in impaired glucose tolerance is cardiovascular system this 
leads to secondary hypertension  associated with half of impaired glucose tolerance 
cases. Macrovascular thrombi ,  Atherosclerosis  will lead to myocardial infarction.  
If  myocardial infarction is diagnosed in patients with impaired glucose tolerance 
then it is better to treat the impact glucose tolerance with  oral hypoglycemic agents. 
 RENAL SYSTEM 
 Both microvascular and macrovascular thrombi causes Papillary Necrosis and 
Nephropathy.  . Asymptomatic microproteinurea  maybe the first clinical clue for 
diagnosing impaired glucose tolerance in clinical side. 
DIAGNOSIS 
 
ORAL GLUCOSE TOLERANCE TEST 
 After 8 to 12 hours of fasting in night 75 gram anhydrous glucose solution has to be 
taken by the patient over a period of 5 minutes. After 2 hours blood sugar level are  
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monitored. If the blood sugar level are in between 140 to 199 impaired glucose 
tolerance is confirmed. 
If patient’s oral glucose tolerance test, 2 hour postprandial blood sugar level is 
between 140 to 199 we can confirm it as impaired glucose tolerance. If the patient 
has a normal fasting sugar and and abnormal oral glucose tolerance test then we have 
to see HbA1c if the value of HbA1cis around 5.7 to 6.5 then impaired glucose 
tolerance or Prediabetes is confirmed .All the Diagnostic procedures like oral 
glucose tolerance test and HbA1c should be repeated twice before committing the 
final diagnosis of Prediabetes. 
TREATMENT OF IMPAIRED FASTING GLUCOSE OR IMPAIRED GLUCOSE 
TOLERANCE  
 It involves  lifestyle modification with 5 to 10% weight reduction and moderate to 
intense physical activity for 30 minutes per day or 40 minutes every alternate days. 
 Individuals with impaired fasting glucose and impaired glucose tolerance and any 
of the following should undergo Lifestyle modification and / or metformin. 
 Age less than 60 years 
  Body mass index more than or equal to 35 kg/m2 
 Family history of diabetes in first degree relatives 
  Elevated triglycerides 
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  Reduced HDL cholesterol 
  Hypertension 
  Hba1cmore than or equal to 6 
 
AIM AND OBJECTIVES 
                       To correlate between Ejection Fraction and HbA1c in Non-Diabetic 
Unstable Angina patients  
 
  
MATERIALS AND METHOD 
PLACE OF STUDY 
Emergency & Medical wards 
Department of Internal Medicine 
Stanley Medical College and Hospital, Chennai 
 
STUDY POPULATION 
                         First 50 non diabetic patients with unstable angina attending the 
emergency ward  in Government Stanley Hospital are included in this study  
STUDY DESIGN 
                          Cross sectional observational study 
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ETHICAL COMMITTEE APPROVAL  
                          Ethical committee approval was obtained for the study 
CASE DEFINITION 
 
 Patients with new onset (< 2 months ) angina , that is severe and /or 
frequent ≥3 episodes / day 
 Patients with accelerating angina that is those with chronic stable angina 
who develop angina that is distinctly more frequent, severe , prolonged or 
precipitated by less exertion than previously 
 Those with angina at  rest. 
 
INCLUSION CRITERIA 
 Non - diabetic  patients diagnosed to have unstable angina 
 
 EXCLUSION CRITERIA 
 Patients with  documented diabetes mellitus 
 ST elevation mi (stemi) 
 Non-ST elevation mi (nstemi) 
 Hba1c ≥ 6.5% or lab tests indicative of diabetes mellitus 
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 History of definite MI, history of congestive heart failure and history of 
chronic kidney disease in the past . 
 Patients with  anemia , pregnancy 
METHODOLOGY 
First 50 Non diabetic Unstable Angina patients admitted to emergency & medical wards at 
Stanley medical college hospital Chennai are included in the present study.  Informed 
consent was obtained from the subjects. Detailed medical history will be collected from 
each patient. Patients were subjected for clinical examination followed by relevant 
investigations. 
The patients undergo the following investigations. 
 Hba1c testing by enzymatic method. 
 Ecg 
 Trans thoracic  Echo is done in each patient and 3-4 cardiac cycles were analysed 
to get best phase for better outcome of results. Ef is calculated by Simpsons method  
 
The first 50 Non diabetic unstable angina patients , admitted in emergency wards 
were subjected to a trans thoracic echocardiography.  
On the basis of ejection fraction they are classified into  
 Ejection fraction less than 50 group 
 Ejection fraction more than or equal to 50 group 
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Serum samples for HbA1c testing will be obtained from each patient  after 
echocardiography. HbA1c testing will  be done by enzymatic method . Then correlation of  
ejection  fraction and HbA1c  will be analysed statistically. 
 
STUDY PERIOD 
          The study period is from march 2017 to September 2017 
HUMAN SUBJECT PROTECTION 
The full protocol along with draft questionnaire and Informed consent will be kept in 
Institutional ethical Committee and approval will be obtained.  
INFORMED CONSENT 
 Consent form will be written in both English and Tamil and consent will be obtained from 
the participant, confidentiality will be maintained. 
 RESULTS AND DISCUSSION 
Descriptive statistics was done for all data and were reported in terms of mean values and 
percentages. Suitable statistical tests of comparison were done. Continuous variables 
were analysed with the unpaired t test.. Categorical variables were analysed with the Chi-
Square Test and Fisher Exact Test. Statistical significance was taken as P < 0.05. The 
data was analysed using  Epi info 7  and Microsoft Excel 2007. 
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STATISTICAL ANALYSIS 
POPULATION  
  
  Frequency Percent 
Valid F 19 38.0 
M 31 62.0 
Total 50 100.0 
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The total population subjected to study is 50 
Among the 50 subjects Males were 31 and Females were 19.  
Males contribute 62% to  the study population 
Females contribute 38 % to  the study population. 
 
 
F, 19
M, 31
SEX PROPORTIONS
F
M
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AGE STATISTICS 
 
 
 
MEAN AGE OF THE POPULATION  
  Obs Total Mean Variance Std Dev 
Frequency Percent Cum % Age  Percent Cum % 
39 1 2.0 56 4 8.0 
40 5 10.0 57 1 2.0 
42 2 4.0 58 3 6.0 
44 1 2.0 59 1 2.0 
45 1 2.0 60 1 2.0 
47 4 8.0 62 3 6.0 
48 1 2.0 63 2 4.0 
49 1 2.0 64 1 2.0 
50 1 2.0 65 1 2.0 
51 2 4.0 66 3 6.0 
54 1 2.0 67 1 2.0 
55 3 6.0 68 2 4.0 
   70 4  
   Total 50  
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 50.0000 2764.0000 55.2800 94.1241 9.7018 
 
  Minimum 25% Median 75% Maximum Mode 
 39.0000 47.0000 56.0000 63.0000 70.0000 40.0000 
 
MEAN AGE  STRATAVAR = SEX 
FEMALES 
  Obs Total Mean Variance Std Dev 
 19.0000 1086.0000 57.1579 96.1404 9.8051 
 
  Minimum 25% Median 75% Maximum Mode 
 40.0000 47.0000 58.0000 66.0000 70.0000 47.0000 
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MALES  
  Obs Total Mean Variance Std Dev 
 31.0000 1678.0000 54.1290 92.4495 9.6151 
 
  Minimum 25% Median 75% Maximum Mode 
 39.0000 47.0000 56.0000 62.0000 70.0000 40.0000 
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Mean age of the population is 55 ( 55.2800 ) 
Mean age stratified sex wise 
 
 
Male 
 
54.1290 
 
Female  
 
57.1579 
 The mean age of females is 54 ( 54.1290) 
 The mean age  of males is 57.15 (57.1579) 
Age groups 55-60 and 65 -70 have highest population frequency . 
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EJECTION FRACTION  
EF Frequency Percent 
40 5 10.00% 
42 1 2.00% 
45 12 24.00% 
46 1 2.00% 
48 10 20.00% 
52 3 6.00% 
55 3 6.00% 
60 4 8.00% 
62 1 2.00% 
63 1 2.00% 
64 1 2.00% 
65 3 6.00% 
66 1 2.00% 
68 4 8.00% 
Total 50 100.00% 
 
Ejection fraction value of 45 % had the maximum frequency of 12 subjects . which 
contribute to 24 % of the entire population . 
Ejection fraction values of 42% , 46 % , 62-64%, 66 %had the least  frequency of 1 
subject . which contribute to 2b % of the entire population  
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EF  Frequency Percent 
BELOW 50 29 58.00% 
MORE THAN OR 
 EQUAL TO 50 
21 42.00% 
Total 50 100.00% 
 
58 percent  ( 29 ) of the population have EF less than 50 % 
42 percent  ( 21 )  of the population have EF more than 50 % 
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In the study population patients with ejection fraction more than or equal to 50 are 
lower in frequency when compared to patients with ejection fraction  less than 50. 
 
MEAN  EF OF STUDY POPULATION  
  Obs Total Mean Variance Std Dev 
 50.0000 2591.0000 51.8200 81.1710 9.0095 
 
  Minimum 25% Median 75% Maximum Mode 
 40.0000 45.0000 48.0000 60.0000 68.0000 45.0000 
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MEAN  EF STRATAVAR =SEX  
FEMALES 
  Obs Total Mean Variance Std Dev 
 19.0000 941.0000 49.5263 70.2632 8.3823 
 
  Minimum 25% Median 75% Maximum Mode 
 40.0000 45.0000 48.0000 55.0000 68.0000 45.0000 
 
MALES 
  Obs Total Mean Variance Std Dev 
 31.0000 1650.0000 53.2258 85.0473 9.2221 
 
  Minimum 25% Median 75% Maximum Mode 
 40.0000 45.0000 48.0000 62.0000 68.0000 45.0000 
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The mean EF of the population is  52 ( 51.82 ) 
The mean EF  of Males is  53 (53. 22) 
The mean EF of  Females is  49.5 ( 49.52 ) 
 
HbA1c STATISTICS 
HBA1C Frequency Percent 
4.9 1 2.00% 
5.1 1 2.00% 
5.2 1 2.00% 
5.3 4 8.00% 
5.4 1 2.00% 
5.5 4 8.00% 
5.6 4 8.00% 
5.7 1 2.00% 
5.8 1 2.00% 
5.9 4 8.00% 
6 1 2.00% 
6.1 9 18.00% 
6.2 7 14.00% 
6.3 5 10.00% 
6.4 6 12.00% 
Total 50 100.00% 
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In the study population HbA1c value of 6.1 had the maximum frequency of 9 
subjects . this contributes to 18 % of the total population. 
 
In the study population HbA1c value of 6.2  had the second highest frequency of 7 
subjects . this contributes to 14 % of the total population. 
 
 
HBA1C Frequency Percent 
BELOW 5.7 16 32.00% 
ABOVE OR  
EQUAL TO 5.7 
34 68.00% 
Total 50 100.00% 
 
32 percent of population have HbA1c less than 5.7 with a frequency of 16 subjects 
68 percent of population have  HbA1c equal to or more than 5.7 with a frequency 
of 34 subjects. 
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In the study population patients with HbA1c more than or equal to 5.7 have two 
fold high frequency when compared to patients with HbA1c less than 5.7 . 
MEAN  HbA1c OF THE  POPULATION 
  Obs Total Mean Variance Std Dev 
 50.0000 295.5000 5.9100 0.1666 0.4082 
 
  Minimum 25% Median 75% Maximum Mode 
 4.9000 5.6000 6.1000 6.2000 6.4000 6.1000 
 
MEANS HbA1c STRATAVAR = SEX 
FEMALES 
  Obs Total Mean Variance Std Dev 
 19.0000 114.5000 6.0263 0.1332 0.3649 
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  Minimum 25% Median 75% Maximum Mode 
 5.2000 5.8000 6.1000 6.3000 6.4000 6.4000 
 
MALES 
  Obs Total Mean Variance Std Dev 
 31.0000 181.0000 5.8387 0.1785 0.4224 
 
  Minimum 25% Median 75% Maximum Mode 
 4.9000 5.5000 6.0000 6.2000 6.4000 6.1000 
 
The mean HbA1c of  the population is  5.9 (5.91) 
The mean HbA1c among Males is  5.9 ( 5.8387) 
The mean HbA1c among Females is 6.0 ( 6.026) 
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AGE AND EJECTION FRACTION  
  EJECTION FRACTION    EJECTION FRACTION  
AGE BELOW 
50  
MORE THAN 
OR EQUAL 
TO 50 
Total AGE  BELOW 
50 
MORE 
THAN OR 
EQUAL TO 
50 
TOTAL 
39 0 1 1 56 4 0 4 
40 2 3 5 57 0 1 1 
42 0 2 2 58 1 2 3 
44 0 1 1 59 1 0 1 
45 0 1 1 60 1 0 1 
47 3 1 4 62 2 1 3 
48 1 0 1 63 1 1 2 
49 0 1 1 64 1 0 1 
50 0 1 1 65 1 0 1 
51 2 0 2 66 2 1 3 
54 1 0 1 67 1 0 1 
55 0 3 3 68 1 1 2 
    70 4 0 4 
     29 21 50 
 
Age group 65-70 had the highest frequency of patients with EF less than 50 
Age group less than 40 & 41- 45 had the highest frequency of patients with EF 
more than or equal to 50  
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In EF less than 50 group maximum frequency of population is in age group 65-70   
EF less than 50 group least  frequency of population is in age group 41-45 .  
In EF ≥ 50 group maximum frequency of population is in age groups less than 40 
& 41-45  and the least frequency is in age group 61-65 years. 
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The assessment of  age group less than 40 years,  patients with EF≥50 years have 
two fold increased frequency when compare to patients with EF <50 . 
The assessment of  age group 65-70 years,  patients with EF<50 years have four 
fold increased frequency when compare to patients with EF ≥50 . 
AGE AND HbA1c CROSS TABULATION 
  HbA1c   
 HbA1c  
AGE 
LESS 
THAN 5.7 
MORE 
THAN OR  
EQUAL TO 
5.7 
Total 
 
 
Age  
LESS 
THAN 
5.7 
MORE 
THAN OR  
EQUAL 
TO 5.7 
Total 
39 1 0 1 57 1 0 1 
40 2 3 5 58 2 1 3 
42 2 0 2 59 0 1 1 
44 1 0 1 60 0 1 1 
45 0 1 1 62 0 3 3 
47 1 3 4 63 1 1 2 
48 0 1 1 64 0 1 1 
49 0 1 1 65 0 1 1 
50 1 0 1 66 0 3 3 
51 0 2 2 67 0 1 1 
54 0 1 1 68 1 1 2 
55 2 1 3 70 0 4 4 
56 1 3 4 TOTAL 16 34 50 
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 In the study population patients with HbA1c more than or equal to 5.7 have two 
fold increased frequency when compared to patients with HbA1c less than 5.7  
 
 
In patients with HbA1c less than 5.7 the maximum frequency of population was in 
age group 56-60 . In patients with HbA1c less than 5.7 the least  frequency of 
population was in age group 61-65 & 65 – 70. 
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In patients with HbA1c more than or equal to 5.7 the maximum frequency of 
population was in age groups 56-60 & 61-70 . In patients with HbA1c more than or 
equal to 5.7 the least  frequency of population was in age groups 41-45. 
 
 
AGE AND SEX  
  SEX    SEX  
AGE FEMALE MALE Total AGE FEMALE MALE Total 
39 0 1 1 57 0 1 1 
40 1 4 5 58 1 2 3 
42 1 1 2 59 0 1 1 
44 0 1 1 60 0 1 1 
45 1 0 1 62 1 2 3 
48 0 1 1 64 1 0 1 
49 0 1 1 65 1 0 1 
50 0 1 1 66 2 1 3 
51 2 0 2 67 0 1 1 
54 0 1 1 68 1 1 2 
55 1 2 3 70 2 2 4 
56 1 3 4 TOTAL  19 31 50 
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The  maximum frequency of  Males are in age group 56-60 . 
The  least frequency of  Males are in age group 41-45 & 61-65. 
The  maximum frequency of  Females are in age group  65-70 
The  least  frequency of  Females are in age group less than 40 . 
 
 
 
When assessing the age group less than 40 years males had five fold increased 
frequency when compare to females  
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When assessing the age group 65- 70 years females and male have similar 
frequency.   
Significant difference in sex ratio is also  seen in age group 56- 60 years  
 
 
HbA1c AND SEX  
    
HBA1C FEMALE MALE Total 
4.9 0 1 1 
5.1 0 1 1 
5.2 1 0 1 
5.3 1 3 4 
5.4 0 1 1 
5.5 0 4 4 
5.6 1 3 4 
5.7 1 0 1 
5.8 1 0 1 
6 0 1 1 
6.1 3 6 9 
6.2 3 4 7 
6.3 2 3 5 
6.4 4 2 6 
TOTAL 19 31 50 
 
In this study HbA1c  values 6.1 and 6.2 had the highest  frequency  of Females and  
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And HbA1c 6.1 had the highest frequency of  Males . 
15 % of Females have HbA1c less than 5.7 
85 % of Females have HbA1c more than or   equal to 5.7 
42 % of Males have HbA1c less than 5.7 
68 % of Males have HbA1c more than or   equal to 5.7 
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LESS THAN 5.7, 
FEMALE, 3, 19%
LESS THAN 5.7, 
MALE, 13, 81%
HbA1c LESS THAN 5.7FEMALE MALE
MORE THAN OR 
EQUAL TO 5.7, 
FEMALE, 16, 47%
MORE THAN OR 
EQUAL TO 5.7, MALE, 
18, 53%
HbA1c MORE THAN OR EQUAL TO 5.7FEMALE MALE
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In HbA1c less than 5.7 group 81 % were Males and 19% were Females. 
The frequency of Males is 4 folds when compared to Females  
In HbA1c more  than or equal to  5.7 group 53 % were Males and 47% were 
Females. 
 
 
EJECTION FRACTION AND HbA1c 
 HbA1C 
EF  LESS THAN 5.7 MORE THAN OR EQUAL TO 5.7 
BELOW 50 1 28 
MORE THAN  
OR EQUAL TO 50  
15 6 
TOTAL 16 34 
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Among the total population  
29 patients ie 58 percent of  total population  had EF less than  50  
21 patients ie 42  percent of  total population  had EF more  than or equal  50  
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In EF less than 50 group  2% of population had HbA1c less than 5.7 
and 30 % had HbA1c more than or equal to 5.7 
In EF more than or equal to  50 group  56% of population had HbA1c less than 5.7 
and 12 % had HbA1c more than or equal to 5.7 
 
In EF less than 50 group 97 % of population had HbA1c more than or equal to 5.7 
and 3% had HbA1c less than 5.7  
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The proportion of patients with HbA1c more  than or equal to 5.7 was  30 folds 
higher than the patients with HbA1c less than 5.7 
 
 
 
In EF more than or equal  50 group 29 % of population had HbA1c more than or 
equal to 5.7 and 71 % had HbA1c less than 5.7 
70 
The proportion of patients with HbA1c less than 5.7  was  2  folds higher than the 
patients with HbA1c more  than or equal to 5.7. 
 
 
Single Table Analysis  
 Point 95% Confidence Interval 
 Estimate  Lower  Upper 
PARAMETERS: Odds-based    
Odds Ratio (cross product) 0.0143 0.0016 0.1300 (T) 
Odds Ratio (MLE) 0.0162 0.0007 0.1139 (M) 
  0.0003 0.1382 (F) 
PARAMETERS: Risk-based    
Risk Ratio (RR) 0.0483 0.0069 0.3376 (T) 
Risk Difference (RD%) -67.9803 -88.4116 -47.5490 (T) 
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In this study group, more than 95 % of patients with EF <50  have HbA1c more 
than 5.7 . More than 70% of patients with EF ≥50  have HbA1c less than 5.7 .   
When extrapolated  ( for 1000 patients ) if EF <50 on1y 14 patients will have 
HbA1c values < 5.7. 
    
    
 
STATISTICAL TESTS Chi-square  1-tailed p  2-tailed p  
Chi-square - uncorrected  25.8675   0.0000003657 
Chi-square - Mantel-Haenszel 25.3502   0.0000004781 
Chi-square - corrected (Yates) 22.8377   0.0000017627 
Mid-p exact  0.0000001639  
Fisher exact  0.0000003237 0.0000003237 
 
 
In this study  Non diabetic unstable  angina patients  who had  EF <50  have   25 
times more chance of having HbA1c more than or equal to 5.7.  
In other words In this study  Non diabetic unstable  angina patients  who had  EF 
>50  have   25 times more chance of having HbA1c less than  5.7. 
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Discussion  
Our study included the first 50 Non diabetic unstable angina patients  admitted in 
emergency ward. In the total population of 50 , Males were 31 contributing 62 %  
and Females were 19 contributing 38 %. The mean age of the population was 55 
years and the mean age among Males and Females were 54 and 57 respectively. 
Among the various age groups  highest population frequency was seen  in age 
intervals 55-60 and 65 – 70. The  maximum frequency of  Males are in age group 
56-60 .The  least frequency of  Males are in age group 41-45 & 61-65. The  
maximum frequency of  Females are in age group  65-70 . The  least  frequency of  
Females are in age group less than 40 . When assessing the age group less than 40 
years males had five fold increased frequency when compare to females .When 
assessing the age group 65- 70 years females and male have similar frequency.   
Significant difference in sex ratio is also  seen in age group 56- 60 years . When 
ejection fractions of the entire population was assessed  , the mean EF was found 
to be 52 where as the mean EF of among Males was 52 and females was 49.5 . Age 
group 65-70 had the highest frequency of patients with EF less than 50 . Age group 
less than 40 & 41- 45 had the highest frequency of patients with EF more than or 
equal to 50 . Highest frequency of  patients were registered in EF value of 45 % 
which contributes to 24 % of the total population. In this study  58 percent  ( 29 ) 
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of the population had  EF less than 50 %. 42 percent  ( 21 )  of the population had 
EF more than or equal to 50 %. Thus  patients with ejection fraction more than or 
equal to 50 are lower in frequency when compared to patients with ejection 
fraction  less than 50. The assessment of  age group less than 40 years indicate that  
patients with EF≥50 years have two fold increased frequency when compare to 
patients with EF <50 . The assessment of  age group 65-70 years reveals that  
patients with EF<50 years have four fold increased frequency when compare to 
patients with EF ≥50 .The mean HbA1c of  the population is  5.9 (5.91)  . The 
mean HbA1c among Males is  5.9 ( 5.8387)  and Females is 6.0 ( 6.026). 15 % of 
Females have HbA1c less than 5.7 .85 % of Females have HbA1c more than or   
equal to 5.7 . 42 % of Males have HbA1c less than 5.7 . 68 % of Males have 
HbA1c more than or   equal to 5.7 . 32 percent of population have HbA1c less than 
5.7 with a frequency of 16 subjects . 68 percent of population have  HbA1c equal 
to or more than 5.7 with a frequency of 34 subjects. In patients with HbA1c less 
than 5.7 the maximum frequency of population was in age group 56-60 . In 
patients with HbA1c less than 5.7 the least  frequency of population was in age 
group 61-65 & 65 – 70. In patients with HbA1c more than or equal to 5.7 the 
maximum frequency of population was in age groups 56-60 & 61-70 . In patients 
with HbA1c more than or equal to 5.7 the least  frequency of population was in age 
groups 41-45. In the study population patients with HbA1c more than or equal to 
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5.7 have two fold high frequency when compared to patients with HbA1c less than 
5.7 . In the study population HbA1c value of 6.1 had the maximum frequency of 9 
subjects . this contributes to 18 % of the total population. In the study population 
patients with HbA1c more than or equal to 5.7 have two fold increased frequency 
when compared to patients with HbA1c less than 5.7 . In HbA1c less than 5.7 
group 81 % were Males and 19% were Females. The frequency of Males is 4 folds 
when compared to Females in this group. In HbA1c more  than or equal to  5.7 
group 53 % were Males and 47% were Females. In the analysis of  EF less than 50 
group  2% of population had HbA1c less than 5.7 and 30 % had HbA1c more than 
or equal to 5.7. In EF more than or equal to  50 group  56% of population had 
HbA1c less than 5.7 and 12 % had HbA1c more than or equal to 5.7. In EF less 
than 50 group 97 % of population had HbA1c more than or equal to 5.7 
and 3% had HbA1c less than 5.7  . The proportion of patients with HbA1c more  
than or equal to 5.7 was  30 folds higher than the patients with HbA1c less than 5.7 
In EF more than or equal  50 group 29 % of population had HbA1c more than or 
equal to 5.7 and 71 % had HbA1c less than 5.7. The proportion of patients with 
HbA1c less than 5.7  was  2  folds higher than the patients with HbA1c more  than 
or equal to 5.7. Finally In this study group, more than 95 % of patients with EF 
<50  have HbA1c more than 5.7 . More than 70% of patients with EF ≥50  have 
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HbA1c less than 5.7 .  When extrapolated  ( for 1000 patients ) if EF <50 on1y 14 
patients will have  HbA1c values < 5.7. 
Thus we are able to say that Non diabetic unstable  angina patients  who had  EF 
<50  have   25 times more chance of having HbA1c more than or equal to 5.7.  
In other words  Non diabetic unstable  angina patients  who had  EF >50  have   25 
times more chance of having HbA1c less than  5.7. 
 
 
CONCLUSION 
Namitha moharthy et al (42) studied the Prognostic implications of glycated 
hemoglobin in nondiabetic patients with acute coronary syndrome in 47 inpatients 
and the results showed that complications were  higher in cases with HbA1c>5.7%. 
This results is  exactly same as our study.  
 
Mahmod salim et al (43 )studied the  association of glycosylated haemoglobin level 
with the severity of coronary artery disease in NSTEMI non diabetic patients. 104 
patients were included in  the study  and the conclusions that showed elevation of  
HbA1C >7% is associated with severe coronary artery disease. This was similar to 
our results 
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Manal et al (44) studied the value of admission glucose and glycosylated hemoglobin 
among patients with acute coronary syndrome.  57   patients were included in the 
study and the conclusion showed HbA1c is a powerful predictor of  LV dysfunction 
in non diabetic NSTEMI patients. This was similar to our study  
 
Saeed alipura (45) et al studied the value of admission hba1c levels in nondiabetic 
patients with unstable angina . 231patients were included in the study  and their data 
analysis revealed that HbA1c was significantly higher in patients with EF < 50% in 
comparison with  EF >50 % group .This was similar to our study  
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LIMITATIONS OF THE STUDY 
1. Sample size included in this study was relatively small. A 
larger number would have strengthened our understanding 
of the correlation between ejection fraction and HbA1c in 
non diabetic unstable angina patients. 
2. First 50 unstable angina patients were selected without 
randomisation into age and sex.  
3. No control groups were assigned in this study .  
4. Single centred study  
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THERAPEUTIC IMPLICATIONS  
 
In our study most of  Non Diabetic unstable angina patients who had ejection fraction 
less than 50 fall into HbA1c more than 5.7 group. If clear- cut correlation has been 
made among ejection fraction and HbA1c in unstable angina then question arises 
whether treating the patients with HbA1c between 5.7 to 6.4 improve the 
cardiovascular outcomes or prevent the patient from going into overt diabetes.   
So I would like to suggest that a high volume multi centred study is reasonable to 
assess the correlation between ejection fraction and HbA1c in Non diabetic unstable 
angina patients . 
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ABBREVIATIONS  
ACS- Acute Coronary Syndrome 
DM-  Diabetes Mellitus  
HbA1C – Haemoglobin A1C 
LDL – Low Density Lipoprotein 
HDL – High Density Lipoprotein 
CAD- Coronary Artery Disease 
STEMI – ST elevation myocardial infarction 
NSTEMI- Non ST elevation myocardial infarction 
EF- Ejection Fraction  
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QUESTIONNAIRE PROFORMA 
 
A STUDY ON CORRELATION OF EJECTION FRACTION AND HBA1C AMONG NON 
DIABETIC UNSTABLE ANGINA PATIENTS 
  
 
NAME:  
AGE:  
SEX:  
ADDRESS:  
TELEPHONE NUMBER:  
OCCUPATION:  
HISTORY OF DIABETES MELLITUS  
DRUG HISTORY:  
PERSONAL HISTORY:  
Alcoholism  
Smoker  
HISTORY: h/o of chest pain  
h/o of previous IHD  
h/o systemic hypertension  
h/o CKD  
h/o surgeries  
h/o alcohol consumption /drinking pattern  
h/o smoking (in pack years)  
h/o Anemia, blood loss, recent blood transfusion  
 
EXAMINATION  
HEIGHT:  
WEIGHT:  
BMI:  
PULSE RATE:  
PERIPHERAL PULSES EXAMINATION:  
BLOOD PRESSURE  
 
PALLOR / ICTERUS/ CYANOSIS/ CLUBBING / PEDAL EDEMA 
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SYSTEM WISE EXAMINATION:  
CVS:  
RS:  
P/A:  
CNS:  
 
INVESTIGATIONS  
Complete blood count:  
Hb:  
ESR:  
TC:  
DC:  
 
HbA1c 
 
SERIAL ECG 
 
ECHOCARDIOGRAPHY 
 
TROPONIN I 
CPK - MB  
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